Search
Teniposide
go.drugbank.com/drugs/DB00444ApprovedInvestigationalTeniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. … Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.
Synonyms: 4'-demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside)Immunoglobulin heavy variable 3-30
go.drugbank.com/bio_entities/BE0004312TargetHumansSecreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414).
Synonyms: Ig heavy chain V-III region BURIndium In-111 pentetate
go.drugbank.com/drugs/DB09425ApprovedInvestigationalDecay of In-111 by electron capture allows for detection with a gamma camera for visualization of the brain and spinal column.
Lumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnLumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver
Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-SteroidalHuman interferon beta
go.drugbank.com/drugs/DB14999ApprovedInvestigationalHuman interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. … It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity.[A191733,L12012]
Lecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023. … [L44537] Lecanemab works to reduce Aβ plaques and prevent Aβ deposition in the brain [A253947,A253952] with high selectivity to Aβ protofibrils.
Technetium Tc-99m tilmanocept
go.drugbank.com/drugs/DB09266ApprovedTechnetium Tc-99m tilmanocept is a radiopharmaceutical diagnostic imaging agent approved by the U.S. … However, as nodal micrometastasis in breast cancer may not be associated with significant changes in survival, it is also important to identify clinically node-negative patients [A32170].
Aripiprazole lauroxil
go.drugbank.com/drugs/DB14185ApprovedAripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia. … Schizophrenia is characterized by positive symptoms such as delusions, hallucinations, thought disorders, and catanoia, and negative symptoms that include social withdrawal, anhedonia, and flattening of
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeElacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigational[A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. … Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist.
Categories: Estrogens, Non-SteroidalBelinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalIt was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget.
Synonyms: (2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE, N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide